Practice pattern for postoperative management of endometrial cancer in Japan: A survey of the Japanese Gynecologic Oncology Group

Yoh Watanabe, Ryo Kitagawa, Daisuke Aoki, Satoshi Takeuchi, Satoru Sagae, Noriaki Sakuragi, Nobuo Yaegashi

研究成果: Article

18 引用 (Scopus)

抄録

Objective: To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG). Method: We conducted an original mail survey regarding the status of postoperative treatment including indication criteria, treatment procedures, and chemotherapeutic regimen among all 226 active member institutions of the JGOG. Results: A total of 199 institutions (88.1%) responded to the survey. A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year. As adjuvant therapy, chemotherapy (79.9%) was significantly (p < 0.01) preferred over radiotherapy (13.0%) or hormonal therapy (7.1%). Furthermore, more than 50% of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90% institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology. A combination of paclitaxel and carboplatin was the most preferred first-line regimen for adjuvant chemotherapy followed by combination regimens consisting of anthracycline and platinum. Conclusion: The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.

元の言語English
ページ(範囲)456-459
ページ数4
ジャーナルGynecologic Oncology
115
発行部数3
DOI
出版物ステータスPublished - 2009 12

Fingerprint

Endometrial Neoplasms
Japan
Gynecology
Obstetrics
Lymph
Endometrioid Carcinoma
Blood Vessels
Adjuvant Chemotherapy
Therapeutics
Histology
Anthracyclines
Carboplatin
Postal Service
Paclitaxel
Surveys and Questionnaires
Platinum
Radiotherapy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

これを引用

Practice pattern for postoperative management of endometrial cancer in Japan : A survey of the Japanese Gynecologic Oncology Group. / Watanabe, Yoh; Kitagawa, Ryo; Aoki, Daisuke; Takeuchi, Satoshi; Sagae, Satoru; Sakuragi, Noriaki; Yaegashi, Nobuo.

:: Gynecologic Oncology, 巻 115, 番号 3, 12.2009, p. 456-459.

研究成果: Article

Watanabe, Yoh ; Kitagawa, Ryo ; Aoki, Daisuke ; Takeuchi, Satoshi ; Sagae, Satoru ; Sakuragi, Noriaki ; Yaegashi, Nobuo. / Practice pattern for postoperative management of endometrial cancer in Japan : A survey of the Japanese Gynecologic Oncology Group. :: Gynecologic Oncology. 2009 ; 巻 115, 番号 3. pp. 456-459.
@article{d25ecd98cb7a484d8eb08d167e2482a0,
title = "Practice pattern for postoperative management of endometrial cancer in Japan: A survey of the Japanese Gynecologic Oncology Group",
abstract = "Objective: To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG). Method: We conducted an original mail survey regarding the status of postoperative treatment including indication criteria, treatment procedures, and chemotherapeutic regimen among all 226 active member institutions of the JGOG. Results: A total of 199 institutions (88.1{\%}) responded to the survey. A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year. As adjuvant therapy, chemotherapy (79.9{\%}) was significantly (p < 0.01) preferred over radiotherapy (13.0{\%}) or hormonal therapy (7.1{\%}). Furthermore, more than 50{\%} of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90{\%} institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology. A combination of paclitaxel and carboplatin was the most preferred first-line regimen for adjuvant chemotherapy followed by combination regimens consisting of anthracycline and platinum. Conclusion: The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.",
keywords = "Adjuvant therapy, Endometrial cancer, Japanese Gynecologic Oncology Group, Survey",
author = "Yoh Watanabe and Ryo Kitagawa and Daisuke Aoki and Satoshi Takeuchi and Satoru Sagae and Noriaki Sakuragi and Nobuo Yaegashi",
year = "2009",
month = "12",
doi = "10.1016/j.ygyno.2009.08.016",
language = "English",
volume = "115",
pages = "456--459",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Practice pattern for postoperative management of endometrial cancer in Japan

T2 - A survey of the Japanese Gynecologic Oncology Group

AU - Watanabe, Yoh

AU - Kitagawa, Ryo

AU - Aoki, Daisuke

AU - Takeuchi, Satoshi

AU - Sagae, Satoru

AU - Sakuragi, Noriaki

AU - Yaegashi, Nobuo

PY - 2009/12

Y1 - 2009/12

N2 - Objective: To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG). Method: We conducted an original mail survey regarding the status of postoperative treatment including indication criteria, treatment procedures, and chemotherapeutic regimen among all 226 active member institutions of the JGOG. Results: A total of 199 institutions (88.1%) responded to the survey. A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year. As adjuvant therapy, chemotherapy (79.9%) was significantly (p < 0.01) preferred over radiotherapy (13.0%) or hormonal therapy (7.1%). Furthermore, more than 50% of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90% institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology. A combination of paclitaxel and carboplatin was the most preferred first-line regimen for adjuvant chemotherapy followed by combination regimens consisting of anthracycline and platinum. Conclusion: The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.

AB - Objective: To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG). Method: We conducted an original mail survey regarding the status of postoperative treatment including indication criteria, treatment procedures, and chemotherapeutic regimen among all 226 active member institutions of the JGOG. Results: A total of 199 institutions (88.1%) responded to the survey. A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year. As adjuvant therapy, chemotherapy (79.9%) was significantly (p < 0.01) preferred over radiotherapy (13.0%) or hormonal therapy (7.1%). Furthermore, more than 50% of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90% institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology. A combination of paclitaxel and carboplatin was the most preferred first-line regimen for adjuvant chemotherapy followed by combination regimens consisting of anthracycline and platinum. Conclusion: The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.

KW - Adjuvant therapy

KW - Endometrial cancer

KW - Japanese Gynecologic Oncology Group

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=70350569304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350569304&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.08.016

DO - 10.1016/j.ygyno.2009.08.016

M3 - Article

C2 - 19765806

AN - SCOPUS:70350569304

VL - 115

SP - 456

EP - 459

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -